85 results about "Diabetic animal" patented technology

The invention discloses a CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 system and application thereof to construction of swine-derived recombinant cells with insulin receptor substrate gene defects. The invention provides an sgRNA (ribonucleic acid) combination which is composed of sgRNAIRS1-1, sgRNAIRS1-3, sgRNAIRS2-2 and sgRNAIRS2-3. The invention provides a plasmid combination. The plasmid combination is composed of four plasmids, and the four plasmids are respectively subjected to transcription to obtain sgRNAIRS1-1, sgRNAIRS1-3, sgRNAIRS2-2 and sgRNAIRS2-3. Theapplication of the sgRNA combination or the plasmid combination is as follows: preparation of recombinant cells; preparation of a diabetic cell model; preparation of a diabetic animal model. Accordingto the invention, sgRNAIRS1-1 is as shown in SEQ ID NO:8; sgRNAIRS1-3 is as shown in SEQ ID NO:10; sgRNAIRS2-2 is shown as SEQ ID NO:14; and sgRNAIRS2-3 is as shown in SEQ ID NO:15. A solid foundation is laid for the preparation of diabetic pig models, and important application value for the research and development of diabetic medicaments is achieved.

The present invention relates to novel antagonists to a B₁-bradykinin (B₁-BK) receptor which have a good affinity and selectivity therefor, some of which being at least partially resistant to enzymatic degradation. The synthesis of the B₁ receptors is induced during inflammation. Symptoms associated with inflammation (elevated hydrostatic pressure and plasma leakage or extravasation) have been observed in diabetic animal models (streptozotocin-induced diabetes (STZ)) as well as in spontaneously hypertensive rats (SHR). The present inventors confirm the presence of B₁-BK receptors in these two models. B₁-BK antagonists abolished the vasocontraction induced by B₁-BK in SHR and STZ, and reduced the glycemia of diabetic animals to normal levels. The present B₁-antagonists are useful for treating any condition wherein B₁-receptor is expressed, particularly during inflammation, and more particularly wherein B₁-receptor expression results in diabetic vasculopathy, other diabetic symptoms associated with an insulitis and a post-capillary resistance building as a consequence of the presence of a B₁-receptor.

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

The invention discloses a method for building an animal model with hyperuricemia-combined diabetes. The method comprises the following steps: 1) feeding an target animal with fodder containing 10% (by mass) of yeast powder; subjecting the target animal to a lavage with a 4% (by mass) adenine water solution according to the following dosage of 100 milligram of adenine per day per kilogram of body weight until the blood uric acid level of the target animal starts falling; 2) halving the dosage of the adenine water solution in step 1), subjecting the target animal to a subcutaneous injection with an oteracil potassium emulsion twice a day according to the following dosage of 100 milligram of oteracil potassium emulsion per day per kilogram of body weight until the target animal shows clinical symptoms of diabetes, and then obtaining the animal model with the hyperuricemia-combined diabetes. The method builds the animal model with the hyperuricemia-combined diabetes for the first time, the animal model has typical disease symptoms, the quantity index has statistical significance, and studies such as glucose clamp test and immunohistochemistry also prove that the modeling is successful. Therefore, the method for building the animal model with the hyperuricemia-combined diabetes is a reliable and practical technique.

The invention provides a separation and purification method of a human umbilical cord mesenchymal stem cell exosome and an application of the human umbilical cord mesenchymal stem cell exosome, and belongs to the technical field of medicines. The human umbilical cord mesenchymal stem cell exosome provided by the invention is prepared by cultivating human umbilical cord mesenchymal stem cells via aserum-free medium, collecting supernatant liquid, implementing centrifuging as well as ultra-filtration and concentration, transferring a concentrated solution onto a 30% sucrose-heavy water densitypad and implementing further purification through sucrose density centrifuging, so that the human umbilical cord mesenchymal stem cell exosome is obtained. According to the separation and purificationmethod that the human umbilical cord mesenchymal stem cell exosome is obtained through separation and purification, immunoreactivity is effectively reduced, and a controllable dosage when the human umbilical cord mesenchymal stem cell exosome is used is guaranteed. The human umbilical cord mesenchymal stem cell exosome, by improving a degree of activating an insulin signaling pathway of a type IIdiabetes animal model, can inhibit composition and decomposition of hepatic glycogen, so that glucose metabolism homeostasis can be achieved; and meanwhile, the sensitivity of the type II diabetes animal model to insulin and an insulin secretion function of pancreatic [beta] cells can be improved and a blood glucose concentration can be reduced, so that the application of the human umbilical cordmesenchymal stem cell exosome to the preparation of medicines for treating type II diabetes can be achieved.

The present invention generally relates to implantable devices for producing insulin in diabetic animals and to methods of making same. Some embodiments include amphiphilic biomembranes for use in biological applications (e.g., as an alternative and/or supplemental insulin source). Some embodiments also include live insulin-producing cells contained within one or more amphiphilic membranes so as to prevent or diminish an immuno-response and/or rejection by the host.

The invention discloses application of an oleanolic acid and retinoic acid pharmaceutical composition to medicament for treating insulin resistance and diabetes. Intraperitoneal injection of the oleanolic acid and retinoic acid pharmaceutical composition to diabetic animal can significantly lower the blood glucose level; and addition of the oleanolic acid and retinoic acid pharmaceutical composition in culture solution for culturing liver cells can significantly promote transmission of an insulin signal. Therefore, the oleanolic acid and retinoic acid pharmaceutical composition can be applied to medicaments for treating diabetes, insulin resistance and metabolic syndrome closely related to insulin resistance.

The invention relates to application of phloretin in preparation of medicine for preventing and treating diabetes. A spontaneous diabetes animal model kkay mouse for transferring Ay genes is introduced, the influence of phloretin on related indexes such as blood glucose and blood fat of diabetes in the mouse is researched, an antidiabetic effect of the phloretin is proved, and a basis is provided for applying the phloretin to the medicine for preventing and treating diabetes.

The invention provides application of resveratrol in medical titanium alloy implants under the condition of diabetes. The application has the advantages that by establishing a medical titanium alloy surface osteogenesis cell culture system, the following key treatment functions of the resveratrol are demonstrated, namely that the cell activity of titanium-bone interface osteogenesis cell in diabetes is improved; the osteogenic differentiation efficiency of the osteogenesis cell is improved; the adhesion state of the osteogenesis cell on the material surface is improved; the capacity of the osteogenesis cell resisting oxidizing stress injury caused by diabetes environment is improved; the pathological apoptosis of the osteogenesis cell is reduced; in addition, the osseointegration effect of the medical titanium alloy implant in a diabetes animal is improved by the resveratrol; the resveratrol can be used as a new drug or titanium alloy implant functional improving composite material ingredient to improve the osseointegration effect of the titanium alloy implant of a diabetes patient.

A prophylactic or therapeutic agent for diabetic maculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula:

wherein X represents a halogen or a hydrogen atom, R¹ and R² concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R¹ and R², together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S, 4S)-6-fluoro-2′,5′-dioxospiro [chroman-4,4′-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia/reperfusion to express edema in a retinal visual cell layer or in a macula lutea

The invention provides a construction method of a type I diabetes animal model. The method comprises the following steps: selecting C57BL/6 mice, performing first tail vein injection, continuously performing intraperitoneal injection of a streptozotocin reagent for 5 days, performing ambrosia for 12 hours before injection, and allowing the mice to freely drink water. Two days after the injection procedure is completed, the ambrosia is carried out for 4 hours, and a glucometer is used for measuring blood glucose until the blood glucose value is 10 mmol/L or above. The statistical analysis of the blood glucose measurement result of the type I diabetes animal model shows that the C57BL/6 mouse type I diabetes model constructed by using the streptozotocin is feasible and can be used for researching the diabetes pathogenesis and the anti-hyperglycemia intervention of medicaments and health-care foods. Compared with the prior art, the C57BL/6 mouse type I diabetes model constructed by the invention has the advantages of high film forming rate, simple operation, no death of animals and good reproducibility.

A method for dedifferentiating adipose tissue stromal cells (ATSC) is provided. When the ATSC is treated under hypoxia condition and with a 4-(3,4-Dihydroxy-phenyl)-derivative (DHP-derivative), expression of stemness genes, cellular growth-related genes and cellular mobility-related genes increase, and expression of histone and DNA methylation-related genes decrease so that cell proliferation increases and pluripotency for differentiating into adipocytes, osteocytes, myocytes, beta cells and cartilage cells is acquired. When the dedifferentiated ATSC is implanted into animal model with spinal cord injury and diabetic animal model, effects of nerve regeneration and increased blood surge level are confirmed. As a result, the method for dedifferentiating the ATSC can be effectively used in the stem cell research, tissue regeneration and development of cytotherapeutic medicines.

The invention relates to the technical field of probiotics, in particular to a composition of lactobacillus paracasei LC-37 and application of the composition in reducing blood sugar. According to the invention, the lactobacillus paracasei LC-37 has new functions of promoting the secretion of the glucagon-like peptide 1, reducing blood sugar and relieving the symptoms of diabetes mellitus; the lactobacillus paracasei LC-37 is further compounded with the dietary fibers, the GLP-1 secretion promoting effect of the lactobacillus paracasei LC-37 is remarkably improved, and the composition of the lactobacillus paracasei LC-37 and the dietary fibers can remarkably reduce the blood glucose of diabetic animals, relieve oral glucose tolerance damage, reduce the insulin resistance index and regulate blood fat. The traditional Chinese medicine composition can improve intestinal mucosal barrier and pancreatic tissue damage, has a certain relieving effect on type II diabetes, and is safe, reliable and free of side effects.

The invention belongs to the technical field of animal models of diabetes mellitus, and particularly relates to a modeling method for an animal model of type 2 diabetes mellitus. The method comprisesthe step that 20-100 lumens and 8-10 hours of illumination is applied during nighttime animal sleep for induction, wherein the induction time is 2-6 month. The method provided by the invention fills the blank of modeling of the animal model of the type 2 diabetes mellitus by a natural induction method, shortens the modeling time of the animal model, and has fewer side effects; and the problems such as too serious obesity and too high mortality of individuals do not easily occur, and feeding costs are greatly reduced.

The invention discloses a method for inducing type 2 diabetes animal model through low-temperature and dietary rhythm regulation and control. By combining the regulation and control of a low-temperature environment with the change of the dietary rhythm of a feeding feed or independently through the change of a dietary rhythm of the feeding feed, or through only the change of the dietary rhythm ofthe feeding feed, the animal is induced to form type 2 diabetes animal model with weight gain, hyperlipidemia, hyperglycemia, hyperinsulinemia and insulin resistance as main markers. Experimental research results show that SD rats can be induced to form main markers of type 2 diabetes such as weight gain, hyperlipidemia, hyperglycemia, hyperinsulinemia and insulin resistance by low-temperature environment and night time-limited diet, the diversity of intestinal microorganisms can be remarkably reduced, the morbidity mode is close to that of human type 2 diabetes, and the constructed diabetes animal model can be used for studying a morbidity mechanism of type 2 diabetes, searching related targets of early diagnosis, and researching and developing treatment drugs and prevention and treatmentmethods.